EP2601198A1 - Novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties - Google Patents
Novel artemisinin-like derivatives with cytotoxic and anti-angiogenic propertiesInfo
- Publication number
- EP2601198A1 EP2601198A1 EP11749777.6A EP11749777A EP2601198A1 EP 2601198 A1 EP2601198 A1 EP 2601198A1 EP 11749777 A EP11749777 A EP 11749777A EP 2601198 A1 EP2601198 A1 EP 2601198A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compounds
- artemisinin
- dha
- cells
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000001772 anti-angiogenic effect Effects 0.000 title description 16
- 231100000433 cytotoxic Toxicity 0.000 title description 4
- 230000001472 cytotoxic effect Effects 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 82
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 18
- 201000011510 cancer Diseases 0.000 claims abstract description 15
- 238000011282 treatment Methods 0.000 claims abstract description 15
- 150000002367 halogens Chemical class 0.000 claims abstract description 4
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 17
- 238000009472 formulation Methods 0.000 claims description 14
- 230000033115 angiogenesis Effects 0.000 claims description 11
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- BJDCWCLMFKKGEE-ISOSDAIHSA-N artenimol Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-ISOSDAIHSA-N 0.000 abstract description 34
- 229960002521 artenimol Drugs 0.000 abstract description 33
- 229930016266 dihydroartemisinin Natural products 0.000 abstract description 33
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 abstract description 7
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 abstract description 6
- 150000002148 esters Chemical class 0.000 abstract description 6
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 abstract description 5
- -1 isopropionate Chemical compound 0.000 abstract description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract description 3
- 150000000138 dihydroartemisinin derivatives Chemical class 0.000 abstract description 3
- 125000001424 substituent group Chemical group 0.000 abstract description 3
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 58
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 30
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 29
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 28
- 229930101531 artemisinin Natural products 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 229960004191 artemisinin Drugs 0.000 description 21
- 101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 18
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 description 17
- 229960004991 artesunate Drugs 0.000 description 17
- 238000003786 synthesis reaction Methods 0.000 description 15
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 10
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 10
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 9
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 9
- 229960002378 oftasceine Drugs 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 210000002257 embryonic structure Anatomy 0.000 description 8
- 210000002889 endothelial cell Anatomy 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 7
- 241000252212 Danio rerio Species 0.000 description 7
- 206010059866 Drug resistance Diseases 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 4
- 108010078791 Carrier Proteins Proteins 0.000 description 4
- 206010034133 Pathogen resistance Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 230000036471 bradycardia Effects 0.000 description 4
- 208000006218 bradycardia Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- BJDCWCLMFKKGEE-KDTBHNEXSA-N Dihydroartemisinin (DHA) Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](O)[C@@H]4C BJDCWCLMFKKGEE-KDTBHNEXSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- YJDYDFNKCBANTM-QCWCSKBGSA-N SDZ PSC 833 Chemical compound C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O YJDYDFNKCBANTM-QCWCSKBGSA-N 0.000 description 3
- 150000001241 acetals Chemical class 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 3
- 210000004781 brain capillary Anatomy 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000007907 direct compression Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229950010938 valspodar Drugs 0.000 description 3
- 108010082372 valspodar Proteins 0.000 description 3
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002622 anti-tumorigenesis Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229910000085 borane Inorganic materials 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
- YHASWHZGWUONAO-UHFFFAOYSA-N butanoyl butanoate Chemical compound CCCC(=O)OC(=O)CCC YHASWHZGWUONAO-UHFFFAOYSA-N 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 238000002737 cell proliferation kit Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000002013 hydrophilic interaction chromatography Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000007154 intracellular accumulation Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- RQHMQURGSQBBJY-UHFFFAOYSA-N (2,2-dichloroacetyl) 2,2-dichloroacetate Chemical compound ClC(Cl)C(=O)OC(=O)C(Cl)Cl RQHMQURGSQBBJY-UHFFFAOYSA-N 0.000 description 1
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 description 1
- PGZVFRAEAAXREB-UHFFFAOYSA-N 2,2-dimethylpropanoyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OC(=O)C(C)(C)C PGZVFRAEAAXREB-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- CFBVWCHTNQHZLT-UHFFFAOYSA-N 4-methoxy-5-[3-(2-methoxy-4-nitro-5-sulfophenyl)-5-(phenylcarbamoyl)tetrazol-3-ium-2-yl]-2-nitrobenzenesulfonate Chemical compound COC1=CC([N+]([O-])=O)=C(S([O-])(=O)=O)C=C1N1[N+](C=2C(=CC(=C(C=2)S(O)(=O)=O)[N+]([O-])=O)OC)=NC(C(=O)NC=2C=CC=CC=2)=N1 CFBVWCHTNQHZLT-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102000041092 ABC transporter family Human genes 0.000 description 1
- 108091060858 ABC transporter family Proteins 0.000 description 1
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 1
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 1
- 240000000011 Artemisia annua Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101000823298 Homo sapiens Broad substrate specificity ATP-binding cassette transporter ABCG2 Proteins 0.000 description 1
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102100021339 Multidrug resistance-associated protein 1 Human genes 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 102000007614 Thrombospondin 1 Human genes 0.000 description 1
- 108010046722 Thrombospondin 1 Proteins 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102100031013 Transgelin Human genes 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- UKXCIQFCSITOCY-VLDCTWHGSA-N anhydrodihydroartemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC=C4C UKXCIQFCSITOCY-VLDCTWHGSA-N 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 229960000981 artemether Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 210000002987 choroid plexus Anatomy 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- BOQMASYCUFVXCR-LHJKONGQSA-N deoxoartemisinin Chemical compound C([C@@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC[C@@H]4C BOQMASYCUFVXCR-LHJKONGQSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000016574 developmental growth Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940120124 dichloroacetate Drugs 0.000 description 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical group OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
- SXYIRMFQILZOAM-HVNFFKDJSA-N dihydroartemisinin methyl ether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OO[C@@]1(C)O4 SXYIRMFQILZOAM-HVNFFKDJSA-N 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- LSACYLWPPQLVSM-UHFFFAOYSA-N isobutyric acid anhydride Chemical compound CC(C)C(=O)OC(=O)C(C)C LSACYLWPPQLVSM-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000002514 liquid chromatography mass spectrum Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000035168 lymphangiogenesis Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 108010066052 multidrug resistance-associated protein 1 Proteins 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000000270 postfertilization Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- MBYLVOKEDDQJDY-UHFFFAOYSA-N tris(2-aminoethyl)amine Chemical compound NCCN(CCN)CCN MBYLVOKEDDQJDY-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000007556 vascular defect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Definitions
- the present invention relates to novel artemisinin-like derivates, and especially dihydroartemisinin derivates and pharmaceutical compositions comprising the present compounds.
- the present invention further relates to the use of the present compounds for the treatment of cancer, especially by oral administration.
- Artemisinin is a natural product of the plant Artemisia annua L. Reduction of artemisinin yields the more active
- DHA dihydroartemisinin
- a compound which is thermally less stable can be further converted into different derivatives, including, for example, artesunate and artemether, which are generally referred to as artemisinins .
- Artemisinins are widely known for their potent antimalarial activity, but also have efficacy in the treatment of several protozoal and schistosomal infections. Artemisinin-like compounds exhibit a wide spectrum of biological activities, including, for example, anti-angiogenic, anti-tumorigenic, and even anti-viral, all of which are of medical importance.
- the anti-tumorigenic activity of the drug is believed to be partly due to iron-dependent generation of reactive oxygen species, as well as alkylation of proteins and DNA.
- Artemisinins inhibit endothelial cell proliferation, cell migration and endothelial tube formation, at least partly by inducing apoptosis. They also interfere with synthesis of vascular endothelial growth factors, possibly via suppression of hypoxia inducible factor (HIF) activation.
- HIF hypoxia inducible factor
- Increased expression of ABC transporters such as P-gp may also enable tumor endothelial cells to escape from anti-angiogenic treatment .
- the clinical efficiency of the present compounds is, for
- the present compounds comprise an R group, either linear or branched, chosen from the group consisting of methyl (Ci), ethyl (C 2 ), propyl (C 3 ) , and butyl (C 4 ) .
- Examples of preferred linear alkyl groups are methyl
- substituents at the hydroxyl group (-0H) of DHA are in this case generally designated as ethanoate (CH 3 ) , propanoate or propionate (C 2 H 5 ) , and butyrate (C 3 H 7 ) , respectively.
- the corresponding substituents at the hydroxyl group (-OH) of DHA are in this case generally designated as isopropanoate or isopropionate (CH(CH3)2) and isobutyrate (C (01.3)3) , respectively.
- a preferred halogen substituent of the present R groups is 01.
- especially preferred R groups are moieties chosen from the group consisting of CH 3 , CHC1 2 , C2H5, C 3 H 7 , and CH(CH 3 ) 2 .
- the compounds according to the present invention are especially suitable to be used in oral formulations allowing oral administration.
- the present invention relates to oral formulations comprising a present compound and a filler or one ore more fillers.
- a suitable fillers according to the present invention is a filler mixture sold under the trade name Prosolv ® SMCC90 (JRS Pharma, Germany) .
- the oral formulation comprises 50% to 90% (w/w) , such as 55%, 60%, 65%, 70%, 75%, 80% or 85%, of a present compound .
- the present oral formulation is in the form of a tablet or capsule.
- the tablets or capsules according to the present invention preferably comprise 80 mg to 220 mg DHA- propionate, such as 85 mg, 90 mg, 95 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, or 210 mg .
- the present inventions relates to the use of the present compounds or oral formulations for the treatment of cancer.
- the present treatment of cancer preferably comprises treatment of cancer by inhibiting
- the present invention relates to the treatment of cancer by oral administration.
- Figure 1 shows the structures of artemisinin, DHA and artesunate .
- Figure 2 shows the conversion of DHA into esters.
- Figure 3 shows the conversion of DHA into ether and amine.
- Figure 4 shows a synthesis scheme for compounds 3, 4, and 5.
- Reagents and conditions (a) NaBH 4 , THF; (b) BF 3 .OEt 2 /Et 3 SiH, CH 2 C1 2 ; (c) BF 3 .OEt 2 , CH 2 C1 2 ; (d) i. BH 3 ,
- Figure 5 shows inhibition of calcein ametoxymethylester efflux from human leukemia CCRF/CEM and CEM/Adr5000 cells by different concentrations of the testing substances - derivatives of artesunate.
- the intracellular accumulation of calcein inside the cells is measured by using FACS analysis.
- the points indicate mean values of fluorescent effect, vertical lines show standard error calculated on the base of two independent experiment replicates. The effect corresponds to a control of cells which were treated only with calcein.
- Figure 6 shows transport of the P-gp substrate NBD-CSA into
- porcine brain capillary lumens in the absence of control and presence of testing substances.
- Figure 7 shows Optical density (OD) as a measure of viable cells at various concentrations of compounds 7, 10 and artemisinin, expressed as percentage of control (VEGF) treated HUVECs .
- OD Optical density
- VEGF control
- DHA dihydroartemisinin
- Tris- ( 2-aminoethyl ) -amine polystyrene resin was obtained from Nova biochem.
- Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker
- LC-MS spectra were recorded on an Agilent 1100 Series HPLC system equipped with a HILIC Silica column (2.1 100 mm, 5 mm, Atlantis HILIC, Waters) coupled with a Bruker Daltonics esquire 3000 plus mass spectrometer (solvent A: H 2 O with 0.1% formic acid, solvent B: ACN with 0.1% formic acid, gradient 2: 90% B to 40% B, 12 min., 0.2 ml/min) .
- Analytical TLC was performed on pre-coated silica gel plates (60 F254, 0.2 mm thick, VWR) , visualization of the plates was accomplished using UV light and/or Iodine staining.
- the dried solvents were purchased from Acros Organics. Artemisinin, dihydroartemisinin and artesunate were provided by Dafra Pharma R&D (Turnhout, Belgium) .
- CCRF-CEM cells counterpart, CCRF-CEM cells were used.
- the cell lines were provided by Dr. Daniel Steinbach (University of Ulm, Ulm,
- CEM/ADR5000 cells have previously been shown to selectively express MDR1 (ABCB1), but none of the other ATP- binding cassette (ABC) transporters.
- the cell lines were
- Fresh stock solutions of each compound were prepared in DMSO at a concentration of 100 mM, and a dilution series was prepared in DMEM.
- Cells were suspended at a final concentration of lxlO 5 cells/ml, and 100 ml were aliquoted per well into a 96- well culture plate (Costar, Corning, USA) .
- Marginal wells were filled with 100 pL of media to minimize evaporation.
- a row of wells with cells was left untreated and another row of wells with cells was treated with 1 pL DMSO, the latter serving as a solvent control. All studies were performed in duplicate, in a range of concentrations, and in two independent experiments with different batches of cells.
- Quantification of cytotoxicity was achieved with an ELISA plate reader (Bio-Rad, Miinchen, Germany) at 490 nm with a reference wavelength of 655 nm, and reported as a percentage of viability compared to untreated cells.
- the ligand binding module of Sigma plot software (version 10.0) was used for analysis .
- Single donor HUVEC cells were purchased from Lonza (Breda, Netherlands) . Cells were seeded at 5,000 cells per well in 96-well microtiterplates in EGM-2EV medium (Invitrogen) . Upon adherence the cells were gently washed twice with PBS and starved overnight in EGM-2EV medium with reduced FBS content (0.1%; starvation medium) . The medium was then aspirated and replaced with starvation medium with or without 30 ng/ml recombinant human VEGF165 (R&D Systems) and with or without increasing concentrations of compound 1 ( artemisinin) , 7 and 10 (0.5-100 ⁇ ) . Due to its precipitation from the cell culture medium, artesunate could not be used as a reference compound.
- PBCECs were isolated from porcine brains as reported. Briefly, freshly isolated porcine brains were collected from the local slaughterhouse, cleaned of meninges, choroid plexus, and superficial blood vessels.
- the tissue was minced into cubes ⁇ 2 mm and incubated in Medium 199, supplemented with 0.8 mM L-glutamine, penicillin/streptomycin (100 U/ml), 100 pg/ml gentamicin, and 10 mM HEPES, pH 7.4 (Biochrom, Berlin, Germany) with dispase II (0.5%) (Roche Diagnostics, Mannheim, Germany) for 2 h at 37°C. After centrifugation at lOOOg for 10 min at 4°C, the supernatant was discarded and the pellet was re- suspended in media containing 15% dextran ( Sigma-Aldrich,
- Micro-vessels were separated by
- the resulting cell suspension was filtered through a 150 pm Polymon ® mesh (NeoLab Migge, Heidelberg, Germany) and centrifuged for 10 min at 130g at 4°C.
- the cell pellet was re- suspended in media containing 9% horse serum (Biochrom) and separated on a discontinuous Percoll (Sigma-Aldrich) gradient consisting of Percoll ® 1.03 g/ml (20 ml) and 1.07 g/ml (15 ml) by centrifugation at lOOOg for 10 min at 4°C.
- Endothelial cells were enriched at the interface between the two Percoll solutions. Cells were collected, washed in media with 9% horse serum at 4°C, and stored with 10% DMSO in liquid nitrogen until use.
- Freshly isolated or recently thawed PBCECs were incubated in DMEM/HAM's F12 1:1 (Biochrom) for lh at 37°C at a cell density of 2.5 ⁇ 10 6 cells/10 ml.
- Test compounds were dissolved in DMSO as stock solutions and further dilutions were made with DMEM/HAM's F12 1:1 (Biochrom) .
- DMSO concentration in the cell suspension did not exceed 1%, a concentration that was determined not to affect the assay.
- a range of concentrations of test compound in a volume of 300-600 pL cell suspension were added, followed by a 15 min incubation at 37°C.
- Calcein-AM 300 pL
- DMEM/HAM's F12 1:1 was added to a final concentration of 1 pM and incubated for 30 min at 37°C. Suspensions were then centrifuged at 200g for 5 min. cells were washed with 4°C DMEM/HAM's F12 1:1, and centrifuged again at 200g for 5 min. at 4°C. The supernatant was discarded and cells were lysed with 600 pL 1% Triton X100 for 10 min on ice. 100 pL of clarified cell lysate was added to 1 well of a 96-well microplate.
- Intracellular fluorescence was measured using a
- Fluorescence-activated cell sorting system FACS: Calibur flow cytometer, Becton-Dickinson, Franklin Lakes, NJ, USA
- Tg ( flil : EGFP) zebrafish which express enhanced green fluorescent protein (GFP) in their endothelial cells, were used as an in vivo model for angiogenesis .
- GFP green fluorescent protein
- zebrafish embryos 10 per well/condition were bathed in fish media, containing a concentration range of each of the compounds or control.
- Compounds had been dissolved as stock solutions in DMSO, stored at room temperature, and serially diluted in fish media prior to use.
- the anti-angiogenic tyrosinase kinase inhibitor SU5416 (Pfizer), and a vehicle-alone control containing the maximum concentration of DMSO were used as controls in all experiments.
- the developmental growth and patterning of the dorsal aorta, posterior cardinal vein, intersomitic vessels (ISV), and vascular plexus (VP) were monitored, as was the heart rate, and blood flow.
- Esters were made by reacting DHA with corresponding anhydrides or acid chloride in basic medium in the presence of triethylamine .
- the ether and amine were synthesized by reacting DHA with a Levis acid forming an oxonium ion, reacting with nucleophiles , such as alcohol or amine, and converted into ether (or amine) derivatives.
- Acetal type C-10 derivatives were more active than non- acetal derivatives 3 and 4.
- the degree of cross-resistance of CEM/ADR5000 cells towards the various compounds ranged from 0.06 (compound 4) to 22.46 (compound 8) .
- alkyl side chains showed high efficacy in terms of activity and cross- resistance when compared to aromatic side chain 13 and
- P-gp inhibitors were chosen as controls, e.g. verapamil and PSC-833.
- Table II EC50 and EC max values of artemisinin derivatives in the calcein-AM assay using multidrug-resistant CEM/ADR5000 cells and flow cytometry.
- Luminal P-gp was inhibited by a well-known selective P-gylcoprotein inhibitor, PSC-833.
- PSC-833 selective P-gylcoprotein inhibitor
- the inhibition of luminal P-gp in porcine brain capillaries by 7 artemisinin derivatives was quantified by fluorospectrometry as shown in Figure 6.
- ISVs intersomitic vessels
- compound 10 is branch-substituted, likely reducing the rate of hydrolysis at C- 10, which may contribute to its greater cytotoxicity as compared with compound 9.
- artesunate is water soluble and
- P-gp transfer system In the treatment of cancer, drug resistance remains a major impediment to success.
- P-gp transfer system One well-characterized pathway that promotes drug resistance is the P-gp transfer system. Its relevance in clinical oncology is well known. For example, P-gp is expressed at the blood brain barrier, thereby hindering the delivery of functionally active anti-tumor drugs to the central nervous system.
- artemisinin and artesunate are well-tolerated in clinical malaria studies, and it is shown herein that the present artemisinin-like compounds also modulate P-gp function, as measured with the calcein assay.
- the present novel artemisinin-like derivatives may enhance tumor cell killing, with lower toxicity, less drug resistance, and improved response rates.
- ABSC ATP-binding cassette
- MRP1, and BCRP and the sensitivity or resistance to artemisinin and 8 different artemisinin derivatives in 55 cell lines of different tumor types (leukemia, colon Ca, breast Ca, lung Ca, prostate Ca, renal ca, brain cancer, ovarian Ca) .
- Collateral sensitivity is a well-known phenomenon in multidrug-resistance cancer cells for more than three decades and led to the development of treatment strategies with
- ROS ROS production may lead to increased cell killing. This view is conceivable with the fact that cell with high P- glycoprotein expression exhibit higher collateral sensitivity than cells with low P-glycoprotein levels.
- Artemisinin Artemisinin
- the Zebra fish model used supports anti-angiogenic properties of the present compounds.
- compounds 9 and 11 suppressed intersomitic vessel (ISV) formation at
- artemisinin, dihydroartemisinin, and artesunate act in an anti- angiogenic manner by interfering with angiogenesis-tegulating genes such as VEGFR, thrombopplastin, thrombospondin 1,
- administration was prepared by direct compression or capsule filling .
- DHA-propionate was recalibrated trough a 710 mm sieve for the preparation of a homogeneous mixture suitable for compression/capsule filling. The obtained particle population under 710 mm is used for further processing. A dry powder mixture was developed for direct compression aiming a 100 mg dosage (DHA-propionate) containing:
Landscapes
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
The present invention relates to novel artemisinin-like derivates, and especially dihydroartemisinin derivates and pharmaceutical compositions comprising the present compounds. The present invention further relates to the use of the present compounds for the treatment of cancer, especially by oral administration. Especially, the present invention relates to dihydroartemisinin compounds (DHA) substituted by, through an ester linkage by a linear or branched C1 to C6 alkyl optionally substituted by one or more halogens. Especially preferred substituents are acetate, propionate, isopropionate, butyrate and isobutyrate,
Description
NOVEL ARTEMISININ—LIKE DERIVATIVES
WITH CYTOTOXIC AND ANTI-ANGIOGENIC PROPERTIES
Description
The present invention relates to novel artemisinin-like derivates, and especially dihydroartemisinin derivates and pharmaceutical compositions comprising the present compounds. The present invention further relates to the use of the present compounds for the treatment of cancer, especially by oral administration.
Artemisinin is a natural product of the plant Artemisia annua L. Reduction of artemisinin yields the more active
dihydroartemisinin (DHA), a compound which is thermally less stable. DHA can be further converted into different derivatives, including, for example, artesunate and artemether, which are generally referred to as artemisinins .
Artemisinins are widely known for their potent antimalarial activity, but also have efficacy in the treatment of several protozoal and schistosomal infections. Artemisinin-like compounds exhibit a wide spectrum of biological activities, including, for example, anti-angiogenic, anti-tumorigenic, and even anti-viral, all of which are of medical importance.
The anti-tumorigenic activity of the drug is believed to be partly due to iron-dependent generation of reactive oxygen species, as well as alkylation of proteins and DNA. The
underlying molecular mechanism by which artemisinins suppress angiogenesis , which in turn, contributes to the anti-tumor activities, are less clear. Nonetheless, direct effects on angiogenesis and lymphangiogenesis have been described.
Artemisinins inhibit endothelial cell proliferation, cell migration and endothelial tube formation, at least partly by inducing apoptosis. They also interfere with synthesis of
vascular endothelial growth factors, possibly via suppression of hypoxia inducible factor (HIF) activation.
Despite of the therapeutic utility of artemisinins in treating malaria, resistant strains of the malaria parasites are emerging, mostly in western Cambodia where treatment failure rates after combination therapy have exceeded 10%. The
mechanisms of resistance are largely unknown, but may replicate some of those that become active in cancer cells as they develop chemo-resistance . These include, among others, mutations in target proteins, resistance to apoptosis, and increased drug efflux via transporters. The latter mechanism is known to be used by parasites to enhance the clearance of drugs, and the multidrug resistance-conferring ATP-binding cassette (ABC) transporter, P-glycoprotein (P-gp) has been implicated.
Increased expression of ABC transporters such as P-gp may also enable tumor endothelial cells to escape from anti-angiogenic treatment .
It is an object of the present invention, amongst other objects, to provide novel artemisinin-like compounds, and especially dihydroartemisinin derivates, with improved clinical efficacy and/or other pharmaceutical properties as compared to non-substituted artemisinin, dihydroartemisinin and artesunate. The clinical efficiency of the present compounds is, for
example, in the field of cancer treatment, especially by
inhibiting angiogenesis .
The above object, amongst other objects, is met by the present invention through the compounds and formulations
described in the appended claims.
Especially, the above object, amongst other objects, is met by the present invention through compounds according to the general formula:
wherein R is a linear or branched Ci to C6 alkyl optionally substituted by one or more halogens.
The present inventors surprisingly discovered that the above compounds are easily synthesized, stable at room
temperature, overcome drug-resistance pathways, and/or are more active in vitro and in vivo than the commonly used artesunate. The provision of the present compounds enables safer and more effective strategies to treat a range of infections and cancer.
According to a preferred embodiment, the present compounds comprise an R group, either linear or branched, chosen from the group consisting of methyl (Ci), ethyl (C2), propyl (C3) , and butyl (C4) .
Examples of preferred linear alkyl groups are methyl
(CH3) , ethyl (C2H5) or propyl (C3H7) . The corresponding
substituents at the hydroxyl group (-0H) of DHA are in this case generally designated as ethanoate (CH3) , propanoate or propionate (C2H5) , and butyrate (C3H7) , respectively.
Examples of preferred branched alkyl groups are
isopropyl (<Η((¾)2) and isobutyl (C (01.3)3) . The corresponding substituents at the hydroxyl group (-OH) of DHA are in this case generally designated as isopropanoate or isopropionate (CH(CH3)2) and isobutyrate (C (01.3)3) , respectively.
A preferred halogen substituent of the present R groups is 01.
According to the present invention, especially preferred R groups are moieties chosen from the group consisting of CH3, CHC12, C2H5, C3H7, and CH(CH3)2.
The compounds according to the present invention are especially suitable to be used in oral formulations allowing oral administration. According to another aspect, the present invention relates to oral formulations comprising a present compound and a filler or one ore more fillers. A suitable fillers according to the present invention is a filler mixture sold under the trade name Prosolv®SMCC90 (JRS Pharma, Germany) .
According to a preferred embodiment of this aspect of the present invention, the oral formulation comprises 50% to 90% (w/w) , such as 55%, 60%, 65%, 70%, 75%, 80% or 85%, of a present compound .
Preferably, the present oral formulation is in the form of a tablet or capsule. The tablets or capsules according to the present invention preferably comprise 80 mg to 220 mg DHA- propionate, such as 85 mg, 90 mg, 95 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, or 210 mg .
According to yet another aspect, the present inventions relates to the use of the present compounds or oral formulations for the treatment of cancer. The present treatment of cancer preferably comprises treatment of cancer by inhibiting
angiogenesis .
According to an especially preferred embodiment of this aspect, the present invention relates to the treatment of cancer by oral administration.
Below, the present invention will be further detailed in the examples of preferred embodiments of the present
invention. In the examples, reference is made to figures
wherein :
Figure 1: shows the structures of artemisinin, DHA and artesunate .
Figure 2: shows the conversion of DHA into esters.
Figure 3: shows the conversion of DHA into ether and amine.
Figure 4: shows a synthesis scheme for compounds 3, 4, and 5.
Reagents and conditions: (a) NaBH4, THF; (b) BF3.OEt2/Et3SiH, CH2C12; (c) BF3.OEt2, CH2C12; (d) i. BH3,
THF; ii. 3M NaOHaq, H202 30%, THF.
Figure 5: shows inhibition of calcein ametoxymethylester efflux from human leukemia CCRF/CEM and CEM/Adr5000 cells by different concentrations of the testing substances - derivatives of artesunate. The intracellular accumulation of calcein inside the cells is measured by using FACS analysis. The points indicate mean values of fluorescent effect, vertical lines show standard error calculated on the base of two independent experiment replicates. The effect corresponds to a control of cells which were treated only with calcein.
Figure 6: shows transport of the P-gp substrate NBD-CSA into
porcine brain capillary lumens in the absence of control and presence of testing substances.
Figure 7: shows Optical density (OD) as a measure of viable cells at various concentrations of compounds 7, 10 and artemisinin, expressed as percentage of control (VEGF) treated HUVECs . Increasing levels of artemisinin-like compounds strongly inhibit proliferation / survival of HUVECs even in the presence of VEGF. Error bars = SEM.
Example 1
Introduction
This example describes the synthesis of several novel artemisinin-like compounds, their in vitro cytotoxic effects, their capacity to alter P-gp function, and their in vivo anti- angiogenic properties. All artemisinin-like compounds
synthesized and tested were based on dihydroartemisinin (DHA) , a breakdown product of artesunate. The biochemical approach was feasible, because the lactol of DHA can be converted into different derivatives, such as ethers and esters, allowing synthesis of a range of different DHA derivatives. The
structures of artemisinin, dihydroartemisinin (DHA) and
artesunate are shown in Figure 1.
Material and Methods Chemistry
Materials and reagents were purchased from Acros
Organics, Beerse, Belgium or Aldrich. Tris- ( 2-aminoethyl ) -amine polystyrene resin was obtained from Nova biochem. Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker
Avance DRX-400 spectrometer (400 MHz) . Coupling constants (J) are reported in Hz. Column chromatography was performed on a
Flashmaster II (Jones Chromatography) with Isolute columns prepacked with silica gel (30e90 mM) for normal phase
chromatography. Melting points were determined with a capillary melting point apparatus (Biichi 510, BUCHI, Flawil, Switzerland) and are uncorrected. Electrospray Ionization (ESI) mass spectra were acquired on an ion trap mass spectrometer (Bruker Daltonics esquire 3000plus) . LC-MS spectra were recorded on an Agilent 1100 Series HPLC system equipped with a HILIC Silica column (2.1
100 mm, 5 mm, Atlantis HILIC, Waters) coupled with a Bruker Daltonics esquire 3000 plus mass spectrometer (solvent A: H2O with 0.1% formic acid, solvent B: ACN with 0.1% formic acid, gradient 2: 90% B to 40% B, 12 min., 0.2 ml/min) . Analytical TLC was performed on pre-coated silica gel plates (60 F254, 0.2 mm thick, VWR) , visualization of the plates was accomplished using UV light and/or Iodine staining.
The dried solvents were purchased from Acros Organics. Artemisinin, dihydroartemisinin and artesunate were provided by Dafra Pharma R&D (Turnhout, Belgium) . Anhydrodihydroartemisinin (4), Deoxoartemisinin (3), 10-Dihydroartemisinyl acetate (7), Compound 5a synthesized by a modified procedure (NaOH/H202 were used as oxidizing agents), 10-dihydroartemisinyl benzoate (13) with small modification (instead of benzoylchloride , the benzoic anhydride was used with catalytic amount of DMAP) were prepared as previously described.
Synthesis of 10-Dihydroartemisinyl 2 ' , 2 ' -Dichloroacetate (8)
DMAP (0.6 g, 4.9 mmol) and dichloroacetic anhydride (6.0 g, 25 mmol) were added to a stirred solution of DHA (5 g, 17.6 mmol) in dichloromethane (300 ml) at 0°C and the reaction mixture was slowly brought to room temperature and stirred for 6 hours, during which time, all DHA was consumed. The solvent was removed under reduced pressure and the residue was purified by flash chromatography with ethyl acetate/hexane (10:90 to 50:50) to provide the product dense liquid (3.82g, 55%) .
1HNMR (400, CDCI3) d 0.86 (d, J = 7.0 Hz, 3 H, 9-Me), 0.97 (d, J = 5.95Hz, 20 3 H, 6-Me), 1.45 (s, 3 H, 3-Me), 1.23- 1.94 (m, 9 H), 2.04 (ddd, J = 14.5, 5.0, 3.0 Hz, 1H) , 2.39 (ddd, J = 14.5, 5.0, 3.0 Hz, 1 H) , 2.55 (m, 1H, H-9), 5.40 (s, 1H, H- 12), 5.90 (d, J = 10.0 Hz, 1 H, H-10), 6.25 (s, 1 H, C0CHC12) ; EIMS (m/z) 396.3 (M+H)+.
Synthesis of 10-Dihydroartemisinyl Butyrate (9)
DMAP (0.6 g, 4.9 mmol) and butyric anhydride (4.0 g, 25 mmol) were added to a stirred solution of DHA (5 g, 17.6 mmol) in dichloromethane (300 ml) at 0°C and the reaction mixture was slowly brought to room temperature and stirred for 8 hours, during which time, all DHA was consumed. The solvent was removed under reduced pressure and the residue was purified by flash chromatography with ethyl acetate/hexane (10:90 to 50:50) . Re- crystallization from ethyl acetate/hexane provided white big crystals (5.9 g, 95%), m.p. 81-85°C.
1HNMR (400, CDC13) d 0.86 (d, J = 7.0 Hz, 3 H, 9-Me), 0.97 (d, J = 5.95 Hz, 3 H, 6-Me), 1.17-1.24 (m, 6 H) , 1.45 (s, 3 H, 3-Me), 1.23-1.94 (m, 9 H) , 2.04 (ddd, J = 14.5, 5.0, 3.0 Hz, 1H) , 2.39 (ddd, J = 14.5, 5.0, 15 3.0 Hz, 1 H) , 2.55 (m, 1H, H- 9), 2.68 (m, 1H, COCH) , 5.45 (s, 1H, H-12), 5.850 (d, J = 10.0 Hz, 1H, H-10) ; EIMS (m/z) 355.4 (M+H)+.
Synthesis of 10-Dihydroartemisinyl propionate (9a)
Synthesis of 10-Dihydroartemisinyl propionate was performed as described for 10-Dihydroartemisinyl Butyrate except propionic anhydride was used instead of butyric anhydride.
1HNMR of 10-Dihydroartemisinyl propionate 1HNMR (400, CDCI3) d 0.91 (d, J = 7.0 Hz, 3 H, 9-Me), 1.03 (d, J = 5.95 Hz, 3 H, 6-Me), 1.17-1.24 (m, 6 H) , 1.50 (s, 3 H, 3-Me), 1.23-1.94 (m, 7 H), 2.04 (ddd, J = 14.5, 5.0, 3.0 Hz, 1H) , 2.39 (ddd, J = 14.5, 5.0, 15 3.0 Hz, 1 H) , 2.55 (m, 1H, H-9), 2.68 (m, 1H) , 5.51 (s, 1H, H-12), 5.87 (d, J = 10.0 Hz, 1H, H-10). ; EIMS (m/z) ... Synthesis of 10-Dihydroartemisinyl butyrate (10)
DMAP (0.6 g, 4.9 mmol) and isobutyric anhydride (4.0 g, 25 mmol) were added to a stirred solution of DHA (5 g, 17.6 mmol) in dichloromethane (200 ml) at 0°C and the reaction
mixture was slowly brought to room temperature and stirred for 8 hours, during which time, all DHA was consumed. The solvent was removed under reduced pressure and the residue was purified by flash chromatography with ethyl acetate/hexane (10:90 to 50:50) to provide the product dense liquid (5.2 g, 84%) .
1HNMR (400, CDC13) d 0.86 (d, J = 7.0 Hz, 3 H, 9-Me), 0.97 (d, J = 5.95 Hz, 3 H, 6-Me), 1.17-1.24 (m, 6 H) 1.45 (s, 3
H, 3-Me), 1.23-1.94 (m, 9 H) , 2.04 (ddd, J = 14.5, 5.0, 3.0 Hz, 1H) , 2.39 (ddd, J = 14.5, 5.0, 15 3.0 Hz, 1 H) , 2.55 (m, 1H, H- 9), 2.68 (m, 1H, COCH) , 5.45 (s, 1H, H-12), 5.850 (d, J = 10.0 Hz, 1H, H-10) ; EIMS (m/z) 355.4 (M+H)+.
Synthesis of 10-Dihydroartemisinyl 2 ' -Propylpentanoate (11)
DMAP (0.5 g, 4.1 mmol) and triethylamine (3.03 g, 30 mmol) were added to a stirred solution of DHA (7.1 g, 25 mmol) in dichloromethane (400 ml) . 2-Proplypentanlychloride (4.87 g, 30 mmol) at -30°C was added, and the reaction mixture was continuously stirred for 2 hours and slowly brought to room temperature and stirred overnight. The solvent was removed under reduced pressure and the residue was purified by flash
chromatography with ethyl acetate/hexane (10:90 to 50:50) to provide the product as a white solid. Re-crystallization from ethyl acetate/hexane resulted in a colorless liquid (8.19 g, 80%) .
1HNMR (400, CDCI3) d 0.86 (d, J = 7.0 Hz, 3 H, 9-Me),
0.90 (t, 6H), 0.97 (d, J = 5.95 Hz, 3 H, 6-Me), 1.33 (m, 4H) ,
I.45 (s, 3 H, 3-Me), 1.64 (m, 4H) , 1.23-1.94 (m, 9 H) , 2.04 (ddd, J = 14.5, 5.0, 3.0 Hz, 1H) , 2.29 (t, 1H) , 2.39 (ddd, J = 14.5, 5.0, 15 3.0 Hz, 1 H) , 2.55 (m, 1H, H-9), 5.45 (s, 1H, H- 12), 5.850 (d, J = 10.0 Hz, 1 H, H-10) ; EIMS (m/z) 411.5
(M+H) +.
Synthesis of 10-Dihydroartemisinyl 2 ' , 2 ' -Dimethylpropianate (12)
DMAP (0.5 g, 4.1 mmol) and trimethylacetic anhydride (5.59 g, 30 mmol) were added to a stirred solution of DHA (7.1 g, 25 mmol) in dichloromethane (400 ml) at 0°C. The reaction mixture was slowly brought to room temperature and stirred overnight, during which time all DHA was consumed. The crude material was washed with water (2x100 ml), and the solvent was removed under reduced pressure. The product was then re- crystallized from ethyl acetate/hexane, yielding white crystals (5.17 g, 75%), m.p. 101-104°C.
1HNMR (400, CDC13) d 0.86 (d, J = 7.0 Hz, 3 H, 9-Me), 0.97 (d, J = 5.95 Hz, 3 H, 6-Me), 1.25 (s, 9H C(CH)3), 1.45 (s, 3 H, 3-Me), 1.23-1.94 (m, 9 H) , 2.04 (ddd, J = 14.5, 5.0, 3.0 Hz, 1H), 2.39 (ddd, J = 14.5, 5.0, 15 3.0 Hz, 1 H) , 2.55 (m, 1H, H- 9), 5.45 (s, 1H, H-12), 5.850 (d, J = 10.0 Hz, 1 H, H-10) ; EIMS (m/z) 369.5 (M+H)+.
Synthesis of 10-Dihydroartemisinyl N' , N' -Dimethylacetamide (14)
DMAP (0.5 g, 4.1 mmol) and dimethylcarbomoyl chloride (3.23 g, 30 mmol) were added to a stirred solution of DHA (7.1 g, 25 mmol) in dichloromethane (400 ml) at 0°C. The reaction mixture was slowly brought to room temperature and stirred for 8 hours, during which time all DHA was consumed. The crude material was washed with water (2x100 ml) and the solvent was removed under reduced pressure. The residue was purified by flash chromatography with ethyl acetate/hexane (10:90 to 90:10), yielding a white dense liquid (5.8g, 65%) .
1HNMR (400, CDCI3) d 0.86 (d, J = 7.0 Hz, 3 H, 9-Me), 0.97 (d, J = 5.95 Hz, 3 H, 6-Me), 1.45 (s, 3 H, 3-Me), 1.23-1.94 (m, 9 H), 2.04 (ddd, J = 14.5, 5.0, 3.0 Hz, 1H) , 2.39 (ddd, J = 14.5, 5.0, 15 3.0 Hz, 1 H) , 2.55 (m, 1H, H-9), 2.92 (s, 3H,
N(CH3)2 , 2.98 (s, 3H, N(CH3)2, 5.45 (s, 1H, H-12), 5.68 (d, J = 10.0 Hz, 1 H, H-10) ; EIMS (m/z) 356.4 (M+H)+.
Synthesis of 10- (2 ' -Butyloxy) Dihydroartemisinin (15)
Boron trifluoride-diethyl ether (3 ml) was added to a stirred solution of DHA (1, 2.56 g, 9.0 mmol) and 2butanol (2.2 g, 30 mmol) in diethyl ether (100 ml) . After 6 hours, the reaction mixture was quenched with saturated aqueous NaHCC>3 and dried with MgS04. Filtration and concentration of the filtrate gave a residue which on flash chromatography with ethyl acetate/ hexane (5:95 to 10:90), yielded a white microcrystalline powder (2.05g, 67%), m.p. 100-101 °C.
1HNMR (400, CDC13) d 0.86 (d, J = 7.0 Hz, 3 H, 9-Me),
0.97 (d, J = 5.95 Hz, 3 H, 6-Me), 1.08 (d, J = 6.1 Hz, 3H) , 1.20 (d, J = 6.2 Hz, 3H), 1.45 (s, 3 H, 3-Me), 1.23-1.94 (m, 9 H) , 2.04 (ddd, J = 14.5, 5.0, 3.0 Hz, 1H) , 2.39 (ddd, J = 14.5, 5.0, 15 3.0 Hz, 1 H), 2.55 (m, 1H, H-9), 4.0 (m, 1H, OCH(CH3)2), 4.87 (d, J = 3.5 Hz, 1 H, H-10), 5.44 (s, 1H, H-12); EIMS (m/z) 341.5 (M+H) +.
Synthesis of 10-Dihydroartemisinyl Thioethylamine (16)
DHA (7.1 g, 25 mmol) and cysteamine (2.7 g, 35 mmol) were dissolved in 300 ml dichloromethane and boron trifluoride- diethyl ether (10 ml) was added slowly at 0°C. The reaction mixture was stirred for 3 hours at 0°C and an additional 1 hour at room temperature. The reaction was quenched with 5% NaHCC>3 and extracted with dichloromethane. The solvent was removed under reduced pressure and the residue was purified by flash
chromatography with ethyl acetate/hexane (10:90) to yield a brown wax product (4.7 g, 55%) .
1HNMR (400, CDC13) d 0.86 (d, J = 7.0 Hz, 3 H, 9-Me), 0.97 (d, J = 5.95 Hz, 3 H, 6-Me), 1.25, 1.45 (s, 3 H, 3-Me), 1.23-1.94 (m, 9 H) , 2.04 (ddd, J = 14.5, 5.0, 3.0 Hz, 1H) , 2.39 (ddd, J = 14.5, 5.0, 15 3.0 Hz, 1 H) , 2.55 (m, 1H, H-9), 2.9 (t, 2H), 3.1 (t, 2H), 4.56 (d, J = 10.0 Hz, 1 H, H-10), 5.31 (s, 1H, H-12) ; EIMS (m/z) 344.5 (M+H)+.
XTT Cytotoxicity Assay
Multidrug-resistant , P-glycoprotein-overexpressing CEM/ADR5000 cells and their parental, drug-sensitive
counterpart, CCRF-CEM cells were used. The cell lines were provided by Dr. Daniel Steinbach (University of Ulm, Ulm,
Germany) .
Doxorubicin resistance of CEM/ADR5000 was maintained as described. CEM/ADR5000 cells have previously been shown to selectively express MDR1 (ABCB1), but none of the other ATP- binding cassette (ABC) transporters. The cell lines were
maintained in RPMI medium (Life Technologies) supplemented with 10% FCS in a humidified 7% CO2 atmosphere at 37°C. Cells were passaged twice weekly. All experiments were done with cells in the logarithmic growth
Cytotoxicity was assessed using the 2 , 3-bis [ 2-methoxy- 4-nitro-5-sulfophenyl ] -2H-tetrazolium-5-carboxanilide inner salt (XTT) assay kit (Roche, Indianapolis, IN), which measures the metabolic activity of viable cells. Toxicity of compounds was determined with the Cell Proliferation Kit II (Roche
Diagnostics, Mannheim, Germany), according to the manufacturer's instructions .
Fresh stock solutions of each compound were prepared in DMSO at a concentration of 100 mM, and a dilution series was prepared in DMEM. Cells were suspended at a final concentration of lxlO5 cells/ml, and 100 ml were aliquoted per well into a 96- well culture plate (Costar, Corning, USA) . Marginal wells were filled with 100 pL of media to minimize evaporation. A row of wells with cells was left untreated and another row of wells with cells was treated with 1 pL DMSO, the latter serving as a solvent control. All studies were performed in duplicate, in a range of concentrations, and in two independent experiments with different batches of cells.
Quantification of cytotoxicity was achieved with an ELISA plate reader (Bio-Rad, Miinchen, Germany) at 490 nm with a reference wavelength of 655 nm, and reported as a percentage of viability compared to untreated cells. The ligand binding module of Sigma plot software (version 10.0) was used for analysis .
HUVEC proliferation/viability assay
Single donor HUVEC cells were purchased from Lonza (Breda, Netherlands) . Cells were seeded at 5,000 cells per well in 96-well microtiterplates in EGM-2EV medium (Invitrogen) . Upon adherence the cells were gently washed twice with PBS and starved overnight in EGM-2EV medium with reduced FBS content (0.1%; starvation medium) . The medium was then aspirated and replaced with starvation medium with or without 30 ng/ml recombinant human VEGF165 (R&D Systems) and with or without increasing concentrations of compound 1 ( artemisinin) , 7 and 10 (0.5-100 μΜ) . Due to its precipitation from the cell culture medium, artesunate could not be used as a reference compound.
After 96 hrs, cell growth was quantified using the
WST1 Rapid cell proliferation kit ( Calbiochem) , and was
expressed in percentage of the control value (VEGF alone) .
Experiments were carried out in triplets. Isolation of Porcine brain capillary endothelial cells (PBCECs)
PBCECs were isolated from porcine brains as reported. Briefly, freshly isolated porcine brains were collected from the local slaughterhouse, cleaned of meninges, choroid plexus, and superficial blood vessels.
After removal of gray matter, the tissue was minced into cubes <2 mm and incubated in Medium 199, supplemented with 0.8 mM L-glutamine, penicillin/streptomycin (100 U/ml), 100 pg/ml gentamicin, and 10 mM HEPES, pH 7.4 (Biochrom, Berlin,
Germany) with dispase II (0.5%) (Roche Diagnostics, Mannheim, Germany) for 2 h at 37°C. After centrifugation at lOOOg for 10 min at 4°C, the supernatant was discarded and the pellet was re- suspended in media containing 15% dextran ( Sigma-Aldrich,
Taufkirchen, Germany) . Micro-vessels were separated by
centrifugation at 5800g for 15 min at 4°C and incubated in 20 ml medium containing collagenase-dispase II (1 mg/ml) (Roche
Diagnostics) for 1.5-2h at 37°C.
The resulting cell suspension was filtered through a 150 pm Polymon® mesh (NeoLab Migge, Heidelberg, Germany) and centrifuged for 10 min at 130g at 4°C. The cell pellet was re- suspended in media containing 9% horse serum (Biochrom) and separated on a discontinuous Percoll (Sigma-Aldrich) gradient consisting of Percoll® 1.03 g/ml (20 ml) and 1.07 g/ml (15 ml) by centrifugation at lOOOg for 10 min at 4°C.
Endothelial cells were enriched at the interface between the two Percoll solutions. Cells were collected, washed in media with 9% horse serum at 4°C, and stored with 10% DMSO in liquid nitrogen until use.
Calcein-AM assay
Freshly isolated or recently thawed PBCECs were incubated in DMEM/HAM's F12 1:1 (Biochrom) for lh at 37°C at a cell density of 2.5χ106 cells/10 ml.
Test compounds were dissolved in DMSO as stock solutions and further dilutions were made with DMEM/HAM's F12 1:1 (Biochrom) . DMSO concentration in the cell suspension did not exceed 1%, a concentration that was determined not to affect the assay. A range of concentrations of test compound in a volume of 300-600 pL cell suspension were added, followed by a 15 min incubation at 37°C. Calcein-AM (300 pL) (MoBiTec,
Gottingen, Germany) in DMEM/HAM's F12 1:1 was added to a final concentration of 1 pM and incubated for 30 min at 37°C.
Suspensions were then centrifuged at 200g for 5 min. cells were washed with 4°C DMEM/HAM's F12 1:1, and centrifuged again at 200g for 5 min. at 4°C. The supernatant was discarded and cells were lysed with 600 pL 1% Triton X100 for 10 min on ice. 100 pL of clarified cell lysate was added to 1 well of a 96-well microplate.
Fluorescence was detected with a Fluoroskan Ascent plate reader (Labsystems, Helsinki, Finland) ( 1 (excitation) =485 nm and 1 (emission) =520 nm) . All concentrations and controls were measured 10-12 times, at least three experiments were performed per test compound.
Flow cytometry
For the calcein-AM assay using flow cytometry, the cell density of suspensions in DMEM/Ham's F12 1:1 was 2.5xl07
cells/ml .
Intracellular fluorescence was measured using a
fluorescence-activated cell sorting system (FACS: Calibur flow cytometer, Becton-Dickinson, Franklin Lakes, NJ, USA) with
1 (excitation) =488 nm and a 530/30 band-pass filter to collect emitted fluorescence. Gating on forward and side scatter in concert with propidium iodide staining allowed distinguishing live endothelial cells.
Twenty thousand cells were sorted in each run, and data were processed and analyzed with CellQuest (Franklin Lakes, NJ, USA) . All fluorescence signals were corrected for background fluorescence. Calcein-AM auto-hydrolysis was measured in control samples (n=6) without cells. The increase in intracellular fluorescence induced by a test compound was compared to control fluorescence levels (100%), and results are reported as
percentage of control.
In vivo experiments
Tg ( flil : EGFP) zebrafish, which express enhanced green fluorescent protein (GFP) in their endothelial cells, were used as an in vivo model for angiogenesis . At 20 hours post- fertilization (hpf), zebrafish embryos (10 per well/condition) were bathed in fish media, containing a concentration range of each of the compounds or control. Compounds had been dissolved as stock solutions in DMSO, stored at room temperature, and serially diluted in fish media prior to use. The anti-angiogenic tyrosinase kinase inhibitor SU5416 (Pfizer), and a vehicle-alone control containing the maximum concentration of DMSO were used as controls in all experiments.
In the first sets of experiments, a broad range of concentrations were used to identify the maximum tolerable dose, based on toxicity to the embryos, visualized directly by light microscopy. Subsequent experiments were performed a minimum of two times. Live analyses of the embryos were performed under light and fluorescence microscopy at 28 hpf and 48 hpf to monitor viability, overall morphology, and pattern of swimming. Angiogenesis was evaluated visually by fluorescence microscopy.
The developmental growth and patterning of the dorsal aorta, posterior cardinal vein, intersomitic vessels (ISV), and vascular plexus (VP) were monitored, as was the heart rate, and blood flow.
Results
Synthesis of compounds
To identify novel artemisinin-like compounds for evaluation of efficacy in different models, we synthesized several acetal and non-acetal derivatives of DHA were
synthesized. Esters (Figure 2) were made by reacting DHA with corresponding anhydrides or acid chloride in basic medium in the
presence of triethylamine . The ether and amine (Figure 3) were synthesized by reacting DHA with a Levis acid forming an oxonium ion, reacting with nucleophiles , such as alcohol or amine, and converted into ether (or amine) derivatives.
In the absence of nucleophiles, it forms an anhydro product 4, or it can be further reduced in the presence of EtsSiH to obtain the product 3. Compound 4 was further converted to alcohol 5a—b (5a major product) by addition of borane followed by hydrogen peroxide and aqueous NaOH (Figure 4.
Cytotoxicity (XTT-assay)
All compounds were tested both towards drug-sensitive CCRF-CEM leukemia cells and their multidrug-resistant subline, CEM/ADR5000. The IC50 values obtained are summarized in Table I below .
Table Cytotoxicity of artemisinin derivatives towards drug- sensitive CCRF-CEM and multidrug-resistant CEM/ADR5000 leukemia cell lines.
Compound CCRF-CEM (μΜ) CEM/ADR5000 (μΜ) Degree of resistance
1 148.05 ± 94.92 ± 30.46 0.64
16.64
2 0.87 ± 0.13 1.84 ± 0.31 2.11
3 240.73 ± 117.38 ± 8.20 0.49
50.68
4 83.36 ± 7.51 33.64 ± 0.68 0.4
5a 156.15 ± 90.03 ± 4.57 0.58
52.05
6 0.55 ± 0.03 0.46 ± 0.03 0.84
7 0.18 ± 0.43 2.36 ± 0.64 12.83
8 1340.96± 87.46 ± 96.84 0.06
1268.63
9 106.00± 25.41 54.99 ± 16.00 0.51
10 12.30 ± 3.86 276.30 ± 213.41 22.46
11 2.68 ± 0.10 3.31 ± 0.24 1.23
12 6.65 ± 1.17 17.64 ± 4.56 2.65
13 171.00 ± 1333.54±507.76 7.79
97.58
14 1.05 ± 0.14 20.75 ± 8.05 19.76
15 16.68 ± 7.34 7.96 ± 3.76 0.47
16 0.86 ± 0.19 3.34 ± 0.64 3.88
Acetal type C-10 derivatives were more active than non- acetal derivatives 3 and 4. The degree of cross-resistance of CEM/ADR5000 cells towards the various compounds ranged from 0.06 (compound 4) to 22.46 (compound 8) . Substitution played an important role in C-10 derivatives. In general, alkyl side chains showed high efficacy in terms of activity and cross- resistance when compared to aromatic side chain 13 and
dichloroacetate side chain 8.
Branched side chain substances possessed more activity than their straight-chain counterparts as in the case of
compounds 9 and 10. When C-10 ether 15 is compared with ester 10, the activity remains the same in both cases, but ether shows slightly less drug-resistance than ester.
Calcein assays
As a next step, it was analyzed whether transport of calcein was affected by artemisinin and its derivatives to asses whether artemisinin-like compounds act as P-glycoprotein
inhibitors .
As is shown in Figure 5, the calcein fluorescence in CCRF-CEM and CEM/ADR5000 cell is low and not different in both cell lines after exposure to artemisinin or artesunate. This indicates that these two drugs do not act as P-gp inhibitors. In
contrast, all other compounds tested led to an intracellular accumulation of calcein in multidrug-resistant CEM/ADR5000 cells, indicating an inhibition of the efflux activity of P-gp.
The EC50 values were in a range from 17.35±1.3 μΜ (11) to 61.8±9.62 μΜ (15) . Intracellular calcein fluorescence
increased from 916% (7) up to 3343% (14) compared to untreated controls, suggesting high affinities of these compounds to P-gp, Table II below. Well-known P-gp inhibitors were chosen as controls, e.g. verapamil and PSC-833.
Table II: EC50 and EC max values of artemisinin derivatives in the calcein-AM assay using multidrug-resistant CEM/ADR5000 cells and flow cytometry.
n.d., not detectable
Inhibition of blood brain barrier function
The inhibitory potential of artemisinin derivatives towards P-gp expressed in porcine capillaries was analyzed by confocal microscopy. Exposure to both compounds 8 and 15
resulted in an almost empty lumen, indicating that the P-gp substrate NBD-CSA accumulated in the endothelial cells,
indicative of inhibition of P-gp. Luminal P-gp was inhibited by a well-known selective P-gylcoprotein inhibitor, PSC-833. The inhibition of luminal P-gp in porcine brain capillaries by 7 artemisinin derivatives was quantified by fluorospectrometry as shown in Figure 6.
Inhibition of angiogenesis in vivo
Eight compounds (4, 7, 8, 9, 10, 11, 12 and 15) were compared to artesunate for their anti-angiogenic potential using an in vivo zebrafish embryo model system (Table III blow) . DMSO at concentrations of 0.5, 1, and 2% was used as vehicle control. No effects were observed on overall morphology, heart rate, blood flow, or angiogenesis in control embryos. The anti- angiogenic agent SU5416 was used as a positive control.
At a concentration of 10 pg/ml, SU5416 completely blocked formation of intersomitic vessels (ISVs) at 28 hpf. At 48 hpf ISVs sprouted only minimally as compared to control embryos. The heart rate was not affected by SU5416, and edema was rarely observed.
Table III: Anti-angiogenic effects in the zebrafish in vivo assay. N = total number of embryos tested (in multiples of 10); Dead = number of dead embryos up to 48 hpf; Vase. Defects = number of surviving embryos with vascular defects; Other = other defects observed : bradycardia (B) or edema (E) .
Compound Cone N Dead Vase . Other
[^g/ml] Defects
Artesunate 25 20 1 0 B
50 20 1 2 B, E
100 20 1 6 B, E
200 10 1 9 B, E
4 50 10 2 0 B
75 10 5 0 B, E
7 0.1 10 1 1 -
1.0 20 2 3 B, E
10 20 3 4 B, E
25 10 0 1 B, E
50 20 4 8 B, E
75 10 3 7 B, E
100 20 4 16 B, E
8 1.0 10 0 2 -
10 10 0 1 B
25 10 0 10 B, E
50 10 0 10 B, E
9 1.0 20 2 4 B
5.0 10 2 2 B, E
10 20 3 6 B, E
15 10 1 9 B, E
25 30 17 13 B, E
50 10 5 5 B, E
10 0.5 10 2 3 B, E
1.0 20 5 7 B, E
10 20 5 10 B, E
11 1.0 30 3 9 B, E
5.0 20 9 11 B, E
10 30 22 8 B, E
12 1.0 10 0 0 B, E
10 10 1 0 B, E
25 10 9 0 B, E
15 1.0 10 0 0 -
10 10 1 0 B
25 10 0 0 B, E
The compounds tested, 7, 8, 9, 10, 11 and artesunate exhibited dose-dependent anti-angiogenic effects. Although there was some inter-experimental variability in the dose-response, compounds 7 and 8 consistently had distinct anti-angiogenic properties. Similarly, compounds 9, 10 and 11 also suppressed angiogenesis , but there was more toxicity than with compounds 7 and 8 at higher doses. Compound 12 was the most toxic at
comparable doses, and a specific anti-angiogenic effect was not observed .
All of the compounds that did suppress angiogenesis were more effective, on a dose-basis, than artesunate. Of note, all compounds induced bradycardia in a dose-dependent manner, and this occurred irrespective of effects on angiogenesis.
Edema, a typical consequence of heart insufficiency, coincided with the bradycardia. Preliminary experiments on rabbit hearts indicate that the bradycardia is unique to the zebrafish and not observed in mammalian models.
Inhibition of VEGF-induced HUVEC proliferation
To further evaluate the anti-angiogenic potential of the present novel compounds, proliferation and survival of human umbilical vein endothelial cells (HUVECs) treated with VEGF and two compounds that were very active in the zebrafish model were assayed .
Artemisinin and VEGF alone served as control and reference compound (Figure 7) . In this assay, despite the presence of the proliferation-inducing VEGF, compounds 7 and 10 inhibited the proliferation and survival of HUVECs significantly stronger than artemisinin. Notably, the survival rate of HUVECs was very poor after more than 48 hours exposure to the compounds when VEGF was omitted.
Discussion
By synthesizing several artemisinin-like derivatives, a range of unique compounds has been identified. It is well known that C-10 derivatives of DHA can act as pro-drugs, and that the introduction of bulky substitutes at this position decreases the rate of hydrolysis beginning with the propionate and
isopropionate and different substitutes.
Thus the resultant compound derivatives may be released more slowly, potentially increasing the circulating half-life and possibly the therapeutic efficacy. Indeed, compound 10 is branch-substituted, likely reducing the rate of hydrolysis at C- 10, which may contribute to its greater cytotoxicity as compared with compound 9.
Additional factors that likely impact on the activity of these compounds are solubility and conversion to DHA. In contrast to artemisinin, artesunate is water soluble and
metabolized to DHA. These distinct properties may at least in part explain the greater cytotoxicity of artesunate as compared to that of artemisinin. This is exemplified the observation that CI 0-derivatives , which are metabolized to DHA, were more
cytotoxic towards cancer cells than C9-derivatives , which cannot be metabolized to DHA. Overall, most of the new derivatives presented are not only generally more active than artemisinin, but were easily synthesized and are stable at room temperature.
In the treatment of cancer, drug resistance remains a major impediment to success. One well-characterized pathway that promotes drug resistance is the P-gp transfer system. Its relevance in clinical oncology is well known. For example, P-gp is expressed at the blood brain barrier, thereby hindering the delivery of functionally active anti-tumor drugs to the central nervous system.
Overcoming drug resistance by using compounds, such as verapamil or PSC-833, that interfere with P-gp function, have
not successfully entered the clinic due to excess toxicity.
Notably, artemisinin and artesunate are well-tolerated in clinical malaria studies, and it is shown herein that the present artemisinin-like compounds also modulate P-gp function, as measured with the calcein assay.
Thus, in combination with classical chemotherapeutic, P-glycoproptein substrates such as vinblastine, paclitaxel, and other anti-tumor drugs, the present novel artemisinin-like derivatives may enhance tumor cell killing, with lower toxicity, less drug resistance, and improved response rates.
As the ATP-binding cassette (ABC) transporter, P- glycoprotein, is not the only drug resistance mechanism, the question arises about the cross-resistance of artemisinin-type compounds to anticancer drugs and about the relevance of other members of the ABC transporter family.
In addition to the doxorubicin-resistant P-glycoprotein over-expressing CEM/ADR5000 cell line, artemisinin and
derivatives were not cross-resistant to MRP-l-overexpressing HL60 leukemia cells and BCRP-overexpressing MDA-MB-231 breast cancer cells. They do not exhibit cross-resistance in cell lines selected for vincristine or epirubicin-resistance, nor to cell lines selected for methotrexate or hydroxyurea. Furthermore, it was found that cisplatin resistant ovarian carcinoma cells were also not cross-resistant to artemisinins .
There was no relationship between expression of P-gp,
MRP1, and BCRP and the sensitivity or resistance to artemisinin and 8 different artemisinin derivatives in 55 cell lines of different tumor types (leukemia, colon Ca, breast Ca, lung Ca, prostate Ca, renal ca, brain cancer, ovarian Ca) .
This result has been confirmed in another cell line panel with 39 cell lines of different tumor origin and
investigation using cell lines derived from Kaposi sarcoma, medularry thyroid carcinoma, and Non-Hodgkin lymphoma. All these
data indicate that artemisinin-type compounds may be active in otherwise drug-resistant cancer cells.
In the present application, it was shown that some artemisinin derivatives exert collateral sensitivity, i.e., doxorubicin-resistant P-glycoprotein over-expressing CEM/ADR5000 cells were more sensitive to these compounds than the parental wild-type CCRF-CEM cells.
Collateral sensitivity is a well-known phenomenon in multidrug-resistance cancer cells for more than three decades and led to the development of treatment strategies with
compounds that selectively kill multi-drug resistant cancer cells, although the mechanisms are still poorly understood.
It has been proposed that compounds extruded by P- glycoprotein consume ATP and repletion of ATP from ADP by oxidative phosphorylation generates reactive oxygen species
(ROS) . ROS production may lead to increased cell killing. This view is conceivable with the fact that cell with high P- glycoprotein expression exhibit higher collateral sensitivity than cells with low P-glycoprotein levels. Artemisinin
derivatives produce ROS leading to apoptosis. Hence, it can be derived that at least some of our derivatives produced more ROS than others leading to higher degrees of collateral sensitivity.
While in vitro evidence supports the notion that several of the present artemisinin-like compounds have benefits, it was important to examine their role in an in vivo model.
The Zebra fish model used supports anti-angiogenic properties of the present compounds. For example, compounds 9 and 11 suppressed intersomitic vessel (ISV) formation at
concentrations as low as 1 pg/ml, above which toxicity became evident. Similarly, compounds 7 and 8 also exhibited anti- angiogenic effects, with somewhat lesser toxicity. When tested in a HUVEC proliferation/survival assay, compounds 7 and 10 were more effective at inhibiting cellular proliferation than
artemisinin, despite the presence of the strong proliferation inducing growth factor VEGF .
The results of the present panel of novel artemisinine derivatives are in accord with previous reports that
artemisinin, dihydroartemisinin, and artesunate act in an anti- angiogenic manner by interfering with angiogenesis-tegulating genes such as VEGFR, thrombopplastin, thrombospondin 1,
plasminogen activator, matrix metalloproteinase 9 etc.
Summarizing, the present results show that the
synthesized artemisinin-like compounds described are not only endowed with different properties in terms of stability and P-gp modulating activity, but that they retain potent in vivo biologic anti-angiogenic properties. Example 2
A solid dosage of DHA-propionate for oral
administration was prepared by direct compression or capsule filling .
DHA-propionate was recalibrated trough a 710 mm sieve for the preparation of a homogeneous mixture suitable for compression/capsule filling. The obtained particle population under 710 mm is used for further processing. A dry powder mixture was developed for direct compression aiming a 100 mg dosage (DHA-propionate) containing:
- 60% DHA-propionate (sieved)
70% filler mixture (Prosolv ®SMCC 90) Upon direct compression at 4 KN with an 8 mm concave punch with fraction bar, the obtained tablets (166 mg) were evaluated. These tablets have friability less than 1% (±0.12%), suitable hardness and a disintegration time of 30 seconds.
Further formulations were developed with higher ratios of DHA-propionate (80%) having also good compressibility and disintegration characteristics nevertheless with higher levels of friability. These produced tablets present a half-white coloration.
Claims
1. Compound according to the general formula:
wherein R is a linear or branched Ci to C6 alkyl optionally substituted by one or more halogens.
2. Compound according to claim 1, wherein R is chosen from the group consisting of a linear or branched methyl, ethyl, propyl, and butyl.
3. Compound according to claim 1 or claim 2, wherein R is chosen from the group consisting of CH3, CHCI2, C2H5, C3H7, and CH(CH3)2.
4. Oral formulation comprising a compound according to any of the claims 1 to 3 and a filler.
5. Oral formulation according to claim 4 comprising 50% to 90% (w/w) of a compound according to any of the claims 1 to
3.
6. Oral formulation according to claim 4 or claim 5 as a tablet or capsule.
7. Oral formulation according to claim 6, wherein said tablet or capsule comprises 80 mg to 220 mg DHA-propionate.
8. Compound according to any of the claims 1 to 3, or an oral formulation according to any of the claims 4 to 7, for the treatment of cancer.
9. Compound, or oral formulation, for the treatment cancer according to claim 8, wherein said treatment comprises inhibiting angiogenesis.
10. Compound, or oral formulation, for the treatment cancer according to claim 8 or claim 9, wherein said treatment comprises oral administration.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11749777.6A EP2601198A1 (en) | 2010-08-03 | 2011-08-03 | Novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2010061264 | 2010-08-03 | ||
PCT/EP2011/063363 WO2012017004A1 (en) | 2010-08-03 | 2011-08-03 | Novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties |
EP11749777.6A EP2601198A1 (en) | 2010-08-03 | 2011-08-03 | Novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2601198A1 true EP2601198A1 (en) | 2013-06-12 |
Family
ID=45558829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11749777.6A Withdrawn EP2601198A1 (en) | 2010-08-03 | 2011-08-03 | Novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties |
Country Status (1)
Country | Link |
---|---|
EP (1) | EP2601198A1 (en) |
-
2011
- 2011-08-03 EP EP11749777.6A patent/EP2601198A1/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO2012017004A1 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Soomro et al. | Design of novel artemisinin‐like derivatives with cytotoxic and anti‐angiogenic properties | |
Liu et al. | Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors | |
Sunassee et al. | Cytotoxicity of lapachol, β-lapachone and related synthetic 1, 4-naphthoquinones against oesophageal cancer cells | |
JP2008505937A (en) | Indoleamine 2,3-dioxygenase (IDO) inhibitor | |
Wang et al. | Synthesis of new ent-labdane diterpene derivatives from andrographolide and evaluation of their anti-inflammatory activities | |
Tang et al. | 1, 10-Seco-Eudesmane sesquiterpenoids as a new type of anti-neuroinflammatory agents by suppressing TLR4/NF-κB/MAPK pathways | |
Kumar et al. | Synthesis and biological evaluation of bergenin-1, 2, 3-triazole hybrids as novel class of anti-mitotic agents | |
Patel et al. | Pyranocarbazole derivatives as potent anti-cancer agents triggering tubulin polymerization stabilization induced activation of caspase-dependent apoptosis and downregulation of Akt/mTOR in breast cancer cells | |
US8183395B2 (en) | Compositions and methods for treating cancer | |
Shang et al. | Design, synthesis of novel celastrol derivatives and study on their antitumor growth through HIF-1α pathway | |
WO2011017998A1 (en) | Gambogic acid cyclization analogues, preparation method and application thereof | |
Cloete et al. | Synthesis, antimalarial activity and cytotoxicity of 10-aminoethylether derivatives of artemisinin | |
US8946246B2 (en) | Synthetic rigidin analogues as anticancer agents, salts, solvates and prodrugs thereof, and method of producing same | |
Hejchman et al. | Synthesis and anticancer activity of 7-hydroxycoumarinyl gallates | |
US20160000750A1 (en) | Combination of egcg or methylated egcg and a pde inhibitor | |
WO2009122447A1 (en) | Semi-synthetic sesquiterpene lactone parthenin compound useful for cytotoxicity against cancer cell lines and anticander agent | |
AU2007271743B2 (en) | Substituted 4-aryl-chromene as activator of caspases and inducer of apoptosis and as antivascular agent and the use thereof | |
Feng et al. | Scaffold hopping of celastrol provides derivatives containing pepper ring, pyrazine and oxazole substructures as potent autophagy inducers against breast cancer cell line MCF-7 | |
WO2012017004A1 (en) | Novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties | |
US6429203B1 (en) | Farnesyl-protein transferase inhibitors | |
EP2601198A1 (en) | Novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties | |
Kapkoti et al. | Design and synthesis of novel glycyrrhetinic acid-triazole derivatives that exert anti-plasmodial activity inducing mitochondrial-dependent apoptosis in Plasmodium falciparum | |
US9006467B2 (en) | 1,2,3-triazole containing artemisinin compounds and process for preparation thereof | |
WO2020001770A1 (en) | Synthesis of (+)-cannabinoids and their therapeutic effects | |
Hu et al. | Synthesis, biological evaluation and preliminary mechanisms of 6-amino substituted harmine derivatives as potential antitumor agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20130225 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20140519 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20140930 |